Key Takeaways
- • Canary Capital and 21Shares have each filed separate ETF applications with the SEC to provide regulated exposure to Injective's INJ token, creating a two-front race for approval as institutional interest in staked crypto products grows.
- • Canary's proposed Staked INJ ETF would distribute staking rewards to shareholders—a differentiated feature designed to simplify token staking for retail and institutional investors who typically lack direct on-chain staking infrastructure.
- • Both ETFs address significant demand from institutional and retail investors seeking regulated pathways into Injective, a layer-1 DeFi protocol, while the SEC continues its comment period review process.
- • The dual filings extend Canary Capital's aggressive crypto ETF filing strategy, which also includes pending applications for XRP, TRON, Litecoin, Hedera, Sui, and PENGU; none have yet received regulatory approval.
- • INJ token gained market attention alongside the ETF filings, with Injective simultaneously expanding retail accessibility through Robinhood's spot trading listing for eligible U.S. users.
Summary
Two institutional asset managers have filed applications with the U.S. Securities and Exchange Commission to launch exchange-traded funds tied to Injective's INJ token, signaling accelerating institutional interest in regulated crypto exposure. Canary Capital and 21Shares have each submitted separate filings, with 21Shares focusing on a spot INJ ETF and Canary proposing a novel staked variant that would distribute periodic staking rewards to ETF shareholders.
Canary Capital's Staked INJ ETF filing, disclosed Thursday, represents a differentiated approach to crypto ETF design. The proposed product would hold INJ directly and stake a portion of assets on-chain while passing staking rewards through to investors—a structure intended to lower technical barriers for retail and institutional participants unfamiliar with self-custody or on-chain staking interfaces. In its filing, Canary cited "significant and growing demand" from both investor classes for regulated Injective exposure. Injective is the native token of a layer-1 blockchain protocol focused on decentralized finance applications and cross-chain interoperability.
Both ETF filings arrive as the SEC opens its formal comment period on the staked INJ proposal, setting the stage for regulatory evaluation. The dual applications reflect broader institutional momentum toward regulated crypto investment vehicles, particularly for layer-1 tokens with active DeFi ecosystems. Canary Capital's filing adds to an expansive pipeline of pending crypto ETF applications from the hedge fund, which is simultaneously seeking SEC approval for products tracking XRP, TRON, Litecoin, Hedera, Sui, and PENGU, though none have yet secured regulatory clearance. Concurrently, Injective expanded retail distribution by launching spot trading on Robinhood Crypto for eligible U.S. users, broadening the token's accessibility beyond institutional and sophisticated retail audiences.
Canary Capital's Staked INJ ETF filing, disclosed Thursday, represents a differentiated approach to crypto ETF design. The proposed product would hold INJ directly and stake a portion of assets on-chain while passing staking rewards through to investors—a structure intended to lower technical barriers for retail and institutional participants unfamiliar with self-custody or on-chain staking interfaces. In its filing, Canary cited "significant and growing demand" from both investor classes for regulated Injective exposure. Injective is the native token of a layer-1 blockchain protocol focused on decentralized finance applications and cross-chain interoperability.
Both ETF filings arrive as the SEC opens its formal comment period on the staked INJ proposal, setting the stage for regulatory evaluation. The dual applications reflect broader institutional momentum toward regulated crypto investment vehicles, particularly for layer-1 tokens with active DeFi ecosystems. Canary Capital's filing adds to an expansive pipeline of pending crypto ETF applications from the hedge fund, which is simultaneously seeking SEC approval for products tracking XRP, TRON, Litecoin, Hedera, Sui, and PENGU, though none have yet secured regulatory clearance. Concurrently, Injective expanded retail distribution by launching spot trading on Robinhood Crypto for eligible U.S. users, broadening the token's accessibility beyond institutional and sophisticated retail audiences.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.